slc

SLC13A5-IN-1 is a selective inhibitor of the sodium-citrate co-transporter (SLC13A5) that completely blocks the uptake of 14C-citrate, with an IC50 of 0.022 μM in HepG2 cells.

(+)-Biotin-SLC, an alkyl chain-based PROTAC linker, is utilized in the synthesis of PROTACs [1].

SLC4011540 is a potent and selective SphK1/2 dual inhibitor with Ki value of 120 nM and 90 nM respectively.

SLC4101431 is a potent SphK2 inhibitor with Ki value of 90 nM.

Progerinin (SLC-D011) is an orally active progerin-lamin A binding inhibitor that alleviates nuclear deformation and growth arrest, suitable for studying Hutchinson-Gilford progeria syndrome (HGPS).

Melanin Concentrating Hormone, salmon acetate (MCH (salmon)) is a 19 amino acid cyclic peptide, is largely expressed in the hypothalamus.

U-104 (NSC-213841) is an effective carbonic anhydrase (CA) inhibitor for CA IX( Ki=45.1 nM) and CA XII(Ki=4.5 nM).

SLC-391 is a selective, orally active AXL inhibitor with an IC50 of 9.6 nM [SLC-391 exhibits antiviral activity].

Biotin-SLC-NHS Ester is a biochemical reagent utilized for labeling cell membrane proteins.

SLC26A3-IN-1 is an inhibitor of the anion-exchange protein SLC26A3 with an IC50 value of 340 nM. SLC26A3, a solute carrier (SLC) protein and member of the SLC26 family, exhibits a wide range of anionic specificities for chloride, bicarbonate, sulfate, and oxalate. Downregulated in adenomas (DRA), SLC26A3 is involved in intestinal absorption of chloride and oxalate and is associated with chloride-losing diarrhea.

SLC5111312 is an inhibitor of SphK1 and SphK2.

SLC7A11-IN-3 (Compound 42711_11) acts as an inhibitor of SLC7A11.

SLC7A11-IN-2 (Compound 1) is an inhibitor of SLC7A11/xCT. It disrupts the oxidative balance in HeLa cells by decreasing intracellular glutathione levels and increasing oxidative stress, thereby inducing cell death with an IC50 of 10.23 μM. Molecular dynamics simulations have demonstrated that SLC7A11-IN-2 exhibits a stronger binding affinity to SLC7A11 compared to Erastin. This compound is useful for research in the field of cervical cancer.

SLC6A8 Corrector 1 is an orally active corrector for mutant SLC6A8 variants, capable of crossing the blood-brain barrier. It is utilized in the study of creatine transporter deficiency (CTD).

SLC3037 is an NLRP3 inhibitor that prevents the binding or oligomerization of NLRP3 with NEK7, thereby inhibiting inflammasome activation triggered by MSU and other activators. It is suitable for research related to gout, cardiovascular diseases, metabolic syndrome, or neurodegenerative diseases.

SLC6A19-IN-1 (Compound 16) is an inhibitor of SLC6A19, useful for studying diseases related to abnormal amino acid levels, such as phenylketonuria (PKU).

AKR1B1/STAT3/SLC7A11-regulator-1 (5a) is a modulator of the AKR1B1/STAT3/SLC7A11 pathway, capable of reversing DOX resistance in MCF-7/ADR cells by enhancing ferroptosis (apoptosis) activity. It is utilized in breast cancer research.

SLC1A1/EAAT3-IN-1 (Compound 3e) is a selective EAAT3 inhibitor with an IC50 of 7.2 μM for hEAAT3, while its IC50 values for EAAT1, EAAT2, and EAAT4 are approximately 250 μM. It is utilized in research related to psychiatric disorders such as obsessive-compulsive disorder and schizophrenia.

SLC26A3-IN-2 is an orally available and highly potent inhibitor of the anion-exchange protein SLC26A3 for the study of constipation. dCMP disodium (2'2'') is a potent inhibitor of the anion-exchange protein SLC26A3.

SLC7A11-IN-1 is an SLC7A11 inhibitor with anti-proliferative and anti-cancer activities. It inhibits cell invasion and metastasis, induces apoptosis and cell cycle arrest. It can be used for research on neurodegenerative diseases.

SLC26A3-IN-3 (compound 4az), a potent SLC26A3 inhibitor with an IC50 of 40 nM, is utilized for constipation and cystic fibrosis research [1].

Anti-SLC40A1 Antibody is a human-derived antibody expressed in CHO cells, targeting SLC40A1, with a predicted molecular weight (MW) of 150 kDa.

SLCB050 is a compound with anticancer activity that inhibits the interaction between DX2 and p14/ARF. It decreases the viability of human lung cancer cells, particularly small cell lung cancer cells, in a p14/ARF-dependent manner, and induces cell apoptosis (apoptosis) and senescence.

LX-6171, a proline transporter (SLC6A7) inhibitor, is used potentially for the treatment of schizophrenia and Alzheimer's disease.